For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook to get a better idea of where it might head:
XBI in Focus
The underlying S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The Biotech Index is a modified equal-weight index. The product charges 35 bps in annual fees (See: All Health Care ETFs).
Why the Move?
The biotech market has regained momentum, supported by favorable regulatory developments, improving clinical data, attractive valuations and an easing macro backdrop. The U.S. biotech sector appears poised for a strong 2026, supported by a pickup in IPO activity. Additionally, rising expectations of further Fed rate cuts this year, and the increasing adoption of AI in U.S. healthcare, continue to provide a meaningful tailwind for the sector.
More Gains Ahead?
Currently, XBI has a Zacks ETF Rank #3 (Hold) with a High risk outlook. It might continue its strong performance in the near term, with a positive weighted alpha of 57.81 (as per Barchart.com), which gives cues of a further rally.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
State Street SPDR S&P Biotech ETF (XBI): ETF Research ReportsThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
